13D Filing: OrbiMed Advisors and Alpine Immune Sciences Inc. (ALPN)

Page 5 of 9 – SEC Filing

(c) The Reporting Persons have not effected any transactions in the Shares during the past sixty (60) days.
(d)  Not applicable.
(e)  As of January 24, 2018, Samuel D. Isaly, who was previously identified as a reporting person, has ceased to be the beneficial owner of more than five percent of the outstanding Shares.
The first paragraph of Item 6 of the Statement is amended to read in full as follows.
Item 6.
Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer
In addition to the relationships between the Reporting Persons described in Items 2 and 5 of the Statement, GP VI is the sole general partner of OPI VI, pursuant to the terms of the limited partnership agreement of OPI VI.  Advisors is the sole managing member of GP VI, pursuant to the terms of the limited liability company agreement of GP VI.  Pursuant to these agreements and relationships, Advisors and GP VI have discretionary investment management authority with respect to the assets of OPI VI.  Such authority includes the power of GP VI to vote and otherwise dispose of securities purchased by OPI VI.  The number of Shares attributable to OPI VI is 3,298,516.  Advisors and GP VI may each be considered to hold indirectly 3,298,516 Shares.
Item 7.
Materials to Be Filed as Exhibits
Exhibit
Description
1.
Joint Filing Agreement among OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC.

Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)